Paris, 27 February 2025 – Mental health has become one of the major challenges facing public health. According to a WHO report published in 2022, more than 280 million people worldwide suffer from depression, and 20 to 30 per cent of patients with depression¹ do not respond to conventional treatments. In light of this, REGEnLIFE, a French medtech company specialising in neurostimulation via photobiomodulation, announces its commitment to enabling patients to benefit from non-pharmacological alternatives and non-invasive alternatives.

His innovative medical device, which works by stimulating both the brain and the gut using photonic emissions in the near-infrared spectrum, is expected to provide a novel therapeutic solution for patients suffering from treatment-resistant depression.